Mattiuzzi, G.N., Cortes, J.E., Blamble, D.A., Bekele, B.N., Xiao, L., Cabanillas, M., … Kantarjian, H. (2010). Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer, 116, 5659–5666.
To compare the efficacy of two schedules of palonosetron versus ondansetron given by continuous IV infusion for treatment of chemotherapy-induced nausea and vomiting (CINV)
The study was conducted at an inpatient setting at the University of Texas M.D. Andersen Cancer Center.
All patients were in active treatment.
This was a randomized prospective study.
Palonosetron was superior to ondansetron in reducing the prevalence of delayed nausea.
The study has potential bias because no control group or blinding was used.
Daily palonosetron appears to be more effective than the alternative used here for the prevention of delayed nausea. All the regimens here were similar in the early days of the therapy course, but palonosetron was significantly better in later days. Findings suggest that different drugs might be more helpful on different days throughout the course of chemotherapy, in concert with patterns seen in nausea.